Why Catalyst Pharmaceuticals Stock Is On Investors’ Radar

Catalyst Pharmaceuticals (CPRX) is drawing attention after recent trading data showed mixed returns, with the share price at $22.79 and total returns varying across the past week, month and past 3 months.

The 1 day share price return of 2.06% comes after a softer patch, with the 30 day share price return of 6.18% and year to date share price return of 1.56% pointing to momentum that has cooled following a much stronger backdrop, including a 3 year total shareholder return of 41.38% and a very large 5 year total shareholder return.

If you are looking beyond a single biopharma name, this is a good moment to see what else is moving using our screen of 35 healthcare AI stocks

With Catalyst shares softening over the past year despite solid revenue and net income figures, and trading below published price targets and some intrinsic value estimates, you need to ask: is this a mispriced rare disease play or is future growth already reflected?

Preferred P/E of 13x: Is it justified?

The market is pricing Catalyst Pharmaceuticals at a P/E of 13x, which screens as good value compared with peers and the sector while the share price sits at $22.79.

The P/E ratio links what investors pay today to the company’s current earnings. For a profitable biopharma with established products in rare diseases, it is a quick way to see how the market weighs earnings power against similar names.

Here, the picture is clear. Catalyst is assessed as good value against its peer average P/E of 32.5x and the wider US biotechs industry at 16.7x. It also trades below an estimated fair P/E of 16x that statistical models suggest the market could move toward if pricing adjusted.

Result: Price-to-earnings of 13x (UNDERVALUED).

However, you still need to weigh concentration in rare disease products, as well as any change in analyst expectations, as potential brakes on the undervaluation story.

Another View: Cash Flows Paint An Even Cheaper Picture

While the 13x P/E points to value against peers and the industry, the SWS DCF model goes further and suggests Catalyst Pharmaceuticals at $22.79 trades below an estimated future cash flow value of $63.33. That gap can look appealing, but what has to go right for the cash flows to line up?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Catalyst Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The valuation signals here are strong, but how they stack up for you depends on your risk tolerance and time frame. Review the details and pressure test the positives by checking the 5 key rewards.

Looking for more investment ideas?

If you stop with just one stock idea, you risk missing out on opportunities that better fit your goals, risk comfort and income needs across the market.

• Target potential mispricing by scanning companies that pair quality fundamentals with attractive valuations using the 52 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by focusing on businesses highlighted in the 68 resilient stocks with low risk scores.
• Hunt for early opportunities in less-followed companies by checking the screener containing 26 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.